A new study demonstrates the ability of the mutant Kras oncogene to use genetic reprogramming to make cells more stem-like and plastic; it resolves the long-standing debate over why Kras is so special in tumor formation. They were also able to identify an effector complex that can be targeted for therapeutic treatment against mutant Kras.